Xeris Biopharma Holdings Inc (XERS)
3.075
+0.04
(+1.15%)
USD |
NASDAQ |
Nov 22, 14:59
Xeris Biopharma Holdings Profit Margin (Quarterly): -29.00% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -29.00% |
| June 30, 2024 | -31.22% |
| March 31, 2024 | -46.71% |
| December 31, 2023 | -30.16% |
| September 30, 2023 | -25.23% |
| June 30, 2023 | -52.20% |
| March 31, 2023 | -50.71% |
| December 31, 2022 | -39.01% |
| September 30, 2022 | -73.44% |
| June 30, 2022 | -103.5% |
| March 31, 2022 | -152.7% |
| December 31, 2021 | -237.0% |
| September 30, 2021 | -235.2% |
| June 30, 2021 | -308.9% |
| March 31, 2021 | -224.7% |
| December 31, 2020 | -296.6% |
| Date | Value |
|---|---|
| September 30, 2020 | -170.1% |
| June 30, 2020 | -1.19K% |
| March 31, 2020 | -1.74K% |
| December 31, 2019 | -1.77K% |
| September 30, 2019 | -10.49K% |
| June 30, 2019 | -11.58K% |
| March 31, 2019 | -10.19K% |
| December 31, 2018 | -2.69K% |
| September 30, 2018 | -2.54K% |
| June 30, 2018 | -1.59K% |
| March 31, 2018 | -4.53K% |
| December 31, 2017 | -1.96K% |
| September 30, 2017 | -4.43K% |
| June 30, 2017 | -926.0% |
| March 31, 2017 | -1.31K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.77K%
Minimum
Dec 2019
-25.23%
Maximum
Sep 2023
-340.6%
Average
-128.1%
Median
Profit Margin (Quarterly) Benchmarks
| Zevra Therapeutics Inc | -899.2% |
| NovaBay Pharmaceuticals Inc | -49.65% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -19.24% |
| Return on Invested Capital | -31.15% |
| Gross Profit Margin (Quarterly) | 74.95% |
| Operating Margin (Quarterly) | -23.76% |
| Return on Net Operating Assets | -26.16% |